Data completeness
1/8 — Limited
Drug data last refreshed 4w ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (11)
Human Mass Balance and Biotransformation Study of [14C]Afuresertib
Started Aug 2022
6 enrolled
Healthy Volunteer
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Started Jul 2022
22 enrolled
Solid TumorNSCLCCervical Cancer+3 more
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Started Feb 2022
256 enrolled
Breast Cancer
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Started Jun 2020
150 enrolled
Platinum-resistant Ovarian Cancer
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Started Sep 2019
49 enrolled
Metastatic Castration-resistant Prostate Cancer
Worked on URESE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.